Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer

Jellvert,Åsa; Franck Lissbrant,Ingela; Edgren,Maliha; Övferholm,Elisabeth; Braide,Karin; Ekelund Olvenmark,Ann-Marie; Kindblom,Jon; Albertsson,Per; Lennernäs,Bo

doi:10.3892/etm.2011.272

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer

Authors:
- Åsa Jellvert
- Ingela Franck Lissbrant
- Maliha Edgren
- Elisabeth Övferholm
- Karin Braide
- Ann-Marie Ekelund Olvenmark
- Jon Kindblom
- Per Albertsson
- Bo Lennernäs
View Affiliations

Affiliations: Department of Oncology, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden, Onkologkliniken, Borås, Sweden
Published online on: May 12, 2011 https://doi.org/10.3892/etm.2011.272
Pages: 579-584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PC) was previously believed to be a chemoresistant disease. In recent years taxane-based chemotherapy has been shown to prolong survival in patients with castration-resistant prostate cancer (CRPC). It remains to be shown, however, which type of chemotherapy provides the most beneficial effect with the least amount of side effects. Seventeen patients with chemonaive CRPC were enrolled in a pilot study evaluating an orally administered chemo-hormonal treatment regimen using a weekly sequential combination called KEES; consisting of ketoconazole in combination with cyclophosphamide or etoposide in combination with estramustine administered on alternate weeks. Prednisone was administered throughout the treatment period. Prostate-specific antigen (PSA) response and acute and chronic toxicities were evaluated. Seventeen patients with CRPC were treated; eleven patients demonstrated a median reduction in PSA of 87% (range 26-99%). Ten (59%) patients responded with a decrease in PSA >50%. Thrombocytopenia and anaemia were the most common side effects. One study fatality was reported, however, it was unclear whether this was treatment related. In conclusion, KEES may be a promising option for patients with CRPC, resulting in a clear reduction in PSA with limited toxicity. Further clinical evaluation of this metronomic chemo-hormonal combination is underway.

View Figures

View References

1.	Damber JE and Aus G: Prostate cancer. Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Calabro F and Sternberg CN: Current indications for chemotherapy in prostate cancer patients. Eur Urol. 51:17–26. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ and Mason MD: Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. CD005247:2006.PubMed/NCBI
4.	Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 17:2506–2513. 1999.PubMed/NCBI
5.	Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Gignac GA, Morris MJ and Hussain M: Castration resistant, taxane-naive metastatic prostate cancer: current clinical approaches and future directions. J Urol. 178:S30–S35. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Bradley DA and Hussain M: Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J. 14:15–19. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 105:1045–1047. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Kerbel RS, Klement G, Pritchard KI and Kamen B: Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 13:12–15. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Kikuchi Y, Kita T, Takano M, Kudoh K and Yamamoto K: Treatment options in the management of ovarian cancer. Expert Opin Pharmacother. 6:743–754. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Stempak D, Seely D and Baruchel S: Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest. 24:432–443. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Tonini G, Schiavon G, Silletta M, Vincenzi B and Santini D: Antiangiogenic properties of metronomic chemotherapy in breast cancer. Fut Oncol. 3:183–190. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 3:2371–2376. 1997.PubMed/NCBI
16.	Lord R, Nair S, Schache A, et al: Low dose metronomic oral cyclophosphamide for hormone-resistant prostate cancer: a phase II study. J Urol. 177:2136–2140. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Millikan R, Thall PF, Lee SJ, et al: Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 21:878–883. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Tu SM, Millikan RE, Mengistu B, et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 357:336–341. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Logothetis CJ and Millikan R: Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol. 26:2423–2424. 2008.PubMed/NCBI
20.	Berruti A, Fara E, Tucci M, et al: Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. Urol Oncol. 23:1–7. 2005.PubMed/NCBI
21.	Bracarda S, Tonato M, Rosi P, et al: Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer. 88:1438–1444. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Dimopoulos MA, Panopoulos C, Bamia C, et al: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology. 50:754–758. 1997. View Article : Google Scholar : PubMed/NCBI
23.	Eigl BJC, Eggener SE, Baybik J, et al: Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 11:4905–4911. 2005. View Article : Google Scholar
24.	Glode LM, Barqawi A, Crighton F, Crawford ED and Kerbel R: Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 98:1643–1648. 2003. View Article : Google Scholar : PubMed/NCBI
25.	Fizazi K, Le Maitre A, Hudes G, et al: Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 8:994–1000. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Wilkinson S and Chodak G: An evaluation of intermediate-dose ketoconazole in hormone-refractory prostate cancer. Eur Urol. 45:581–585. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Harris KA, Weinberg V, Bok RA, Kakefuda M and Small EJ: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 168:542–545. 2002. View Article : Google Scholar : PubMed/NCBI
28.	Haines IE and Stanley RM: Perspective on ‘Chemotherapy for advanced prostate cancer: 25 years later’: Is it a mirage or an oasis? J Clin Oncol. 26:4049–4051. 2008.